Health Discovery Corporation Announces Publication of Peer Reviewed Scientific Paper Demonstrating the Clinical Validity of the Four-Gene Prostate Cancer Test Licensed to Abbott GmbH, Quest Diagnostics Inc. and Clarient, Inc.

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company specializing in personalized medicine, announced today that its scientific paper entitled “A Four-Gene Expression Signature for Prostate Cancer Cells Consisting of UAP1, PDLIM5, IMPDH2, and HSPD1” has successfully completed the peer review process and has been approved for publication in the August issue of UroToday International Journal. This publication demonstrates the clinical validity of the four-gene prostate cancer test for identifying clinically significant prostate cancer licensed for commercialization by HDC to Abbott (NYSE: ABT), Quest Diagnostics (NYSE: DGX), and Clarient (NasdaqCM: CLRT).